Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faster-acting insulin aspart vs NovoRapid in type 1 diabetes (Onset 5)
NCT02825251Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2016
- Primary completion
- Jun 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
A Phase 3 trial of insulin aspart in type 1 diabetes mellitus (T1D), sponsored by Novo Nordisk. Started Jul 2016; status: completed.
02
Drugs
insulin aspart
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02825251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02825251.